The antibacterial spectrum is similar to that of erythromycin. It is effective against Gram-positive bacteria and some Gram-negative bacteria, mycoplasmas, rickettsiae, spirochetes, etc. It is mainly used for penicillin-resistant Staphylococcus, Streptococcus, and Streptococcus pneumoniae infections.

This product is an aromatic propionic acid derivative and a non-steroidal anti-inflammatory analgesic. In addition to inhibiting cyclooxygenase, this product also has a certain effect of inhibiting lipoxygenase and reducing bradykinin, thereby reducing the pain sensation at the site of inflammation and injury. Because bradykinin and prostaglandins can cause pain together. Bradykinin can also cause uterine contraction, so this product is used for dysmenorrhea, mainly by inhibiting bradykinin, thereby inhibiting uterine contraction and analgesia to achieve therapeutic effects. This product also has a certain central analgesic effect.

This product is a non-steroidal anti-inflammatory drug with a fast onset of action. It may produce analgesic, anti-inflammatory and antipyretic effects mainly by inhibiting the synthesis of prostaglandins. This product has no accumulation effect.

Meropenem binds to penicillin-binding proteins (PBPs) involved in cell wall synthesis through its covalent bond, thereby inhibiting the synthesis of bacterial cell walls and exerting an antibacterial effect. Meropenem is sensitive to both Gram-positive and Gram-negative bacteria, and has a particularly strong antibacterial activity against Gram-negative bacteria.

This product is an H2 receptor antagonist, which can significantly inhibit the basal and nocturnal gastric acid secretion of normal people and ulcer patients, as well as the gastric acid secretion caused by pentagastrin, histamine and meals, and has a certain inhibitory effect on the secretion of pepsinogen. It has a protective effect on experimental gastric mucosal damage and acute ulcers. It has no effect on the secretion of gastrin and sex hormones.